Conference
Double-blinded, Placebo-controlled Randomized Study Evaluating the Efficacy of Risedronate to Prevent the Loss of Bone Mineral Density in Non-metastatic Prostate Cancer Patients Undergoing Radiotherapy Plus 2-3 Years of Androgen Ablation Therapy
Authors
Choo C; Lukka H; Kiss A; Danjoux C
Volume
81
Publisher
Elsevier
Publication Date
January 1, 2011
DOI
10.1016/j.ijrobp.2011.06.086
Conference proceedings
International Journal of Radiation Oncology • Biology • Physics
Issue
2
ISSN
0360-3016